Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300013 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
A Phase 2 study of Heart Failure, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 614
- Enrollment target
- 20
- Study locations
NCT01300013: Completed Phase 2 study of Heart Failure, sponsored by Cytokinetics.
NCT01300013 is a Phase 2 study of Heart Failure that has completed, run by Cytokinetics. The registered enrollment target is 614 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01300013, a Phase 2 study of Heart Failure, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 614 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to omecamtiv mecarbil or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omecamtiv mecarbil
Study Locations (20)
Florida
- Research Site - Atlantis
- Research Site - Clearwater
- Research Site - Fort Lauderdale
- Research Site - Miami
- Research Site - Orlando
California
- Research Site - Inglewood
- Research Site - La Jolla
- Research Site - San Francisco
Michigan
- Research Site - Detroit
- Research Site - Detroit
- Research Site - Novi
Illinois
- Research Site - Chicago
- Research Site - Peoria
Alabama
- Research Site - Mobile
Connecticut
- Research Site - Danbury
Delaware
- Research Site - Newark
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01300013 record still lists
NCT01300013 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01300013 names 20 study sites across 11 states, led by Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT01300013 about?
NCT01300013 is a clinical study titled "Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)". The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-contr...
What is the current status of trial NCT01300013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 614 participants. The study started on 2011-04. Estimated completion is 2013-09.
What conditions does trial NCT01300013 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01300013?
The interventions under investigation include: Placebo (DRUG), Omecamtiv mecarbil (DRUG).
Who is sponsoring clinical trial NCT01300013?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01300013 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01300013's enrollment target sits among peer trials
614 91st of 397 higher than 307 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- NCT07409272 · 614 participants · Phase 3
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia